Search results for "PROTEIN KINASE"

showing 10 items of 1188 documents

Angiotensin-Converting Enzyme Inhibitor Ramiprilat Interferes With the Sequestration of the B 2 Kinin Receptor Within the Plasma Membrane of Native E…

1999

Background —ACE (kininase II) inhibitors have been shown to exert their beneficial cardiovascular effects via the inhibition of both angiotensin II formation and bradykinin breakdown. Because recent evidence suggests that ACE inhibitors may also interfere with B 2 kinin receptor signaling and thus enhance the vascular response to bradykinin, we examined whether the distribution of B 2 kinin receptors within the plasma membrane of native endothelial cells is affected by an ACE inhibitor. Methods and Results —Localization of the B 2 kinin receptor in membranes prepared from native porcine aortic endothelial cells was evaluated by means of specific [ 3 H]bradykinin binding and immunoprecipita…

medicine.medical_specialtyReceptor Bradykinin B2SwineBradykininAngiotensin-Converting Enzyme InhibitorsPharmacologyBradykininchemistry.chemical_compoundRamiprilPhysiology (medical)Internal medicinemedicineAnimalsCalcium SignalingBradykinin receptorReceptorAortaMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3biologyReceptors BradykininMembrane ProteinsBiological TransportAngiotensin-converting enzymeKininAngiotensin IIEndothelial stem cellEndocrinologychemistryCalcium-Calmodulin-Dependent Protein Kinasesbiology.proteinEndothelium VascularMitogen-Activated Protein KinasesCardiology and Cardiovascular MedicineRamiprilatSignal TransductionCirculation
researchProduct

Effects of sodium fluoride on the mechanical activity in mouse gastric preparations.

2005

The aim of the present study was to investigate the responses induced by sodium fluoride (NaF) on gastric mechanical activity, using mouse whole-stomach preparations. The mechanical activity was recorded in vitro as changes of intraluminal pressure. In most of the preparations, NaF induced a tetrodotoxin-insensitive biphasic effect characterized by early relaxation followed by slowly developing contractile response. The contraction was dependent on the concentration of NaF, whereas the relaxation was observed at only 10–30 mmol/L NaF. The contractile effect was significantly reduced by nifedipine (an L-type Ca2+channel blocker), ryanodine or ruthenium red (inhibitors of Ca2+release from sar…

medicine.medical_specialtyRuthenium redPhysiologySettore BIO/09 - FisiologiaAdenylyl cyclasechemistry.chemical_compoundMiceNifedipinePhysiology (medical)Internal medicineSodium fluoridemedicineAnimalsChannel blockerEnzyme InhibitorsProtein Kinase CPharmacologyPhospholipase CRyanodine receptorStomachGastric mechanical activity Mouse stomach Smooth muscle Sodium fluorideMuscle SmoothGeneral MedicineNeomycinMice Inbred C57BLEndocrinologychemistryType C PhospholipasesAdenylyl Cyclase InhibitorsSodium FluorideCalciumExtracellular SpaceGastrointestinal Motilitymedicine.drugAdenylyl CyclasesMuscle ContractionCanadian journal of physiology and pharmacology
researchProduct

Differential regulation of interleukin-6 expression in human fibroblasts by tumor necrosis factor-alpha and lymphotoxin.

1990

The treatment of human diploid fibroblasts with tumor necrosis factor (TNF)-alpha and with lymphotoxin (LT) is associated with induction of interleukin-6 (IL-6) transcripts with TNF-alpha being 10-fold more potent than LT. Here we report on the TNF-alpha/LT-induced signaling mechanisms responsible for the regulation of IL-6 gene expression in these cells. Run-on assays demonstrated that both TNF-alpha and LT increase IL-6 mRNA levels by transcriptional activation of this gene. Stability studies of IL-6 transcripts in fibroblasts showed that TNF-alpha delayed IL-6 mRNA decay but not LT. The induction of IL-6 transcripts by TNF-alpha and LT was not inhibited by the isoquinoline sulfonamide de…

medicine.medical_specialtyTime FactorsTranscription Geneticmedicine.medical_treatmentCellular differentiationBiophysicsCycloheximideBiologyBiochemistrychemistry.chemical_compoundStructural BiologyInternal medicineGene expressionGeneticsmedicineHumansRNA MessengerMolecular BiologyLymphotoxin-alphaProtein kinase CCells CulturedProtein Kinase CInterleukin-6Tumor Necrosis Factor-alphaCell BiologyFibroblastsMolecular biologyKineticsCytokineLymphotoxinEndocrinologychemistryGene Expression RegulationProtein BiosynthesisTumor necrosis factor alphaSignal transductionFEBS letters
researchProduct

Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis.

2014

Aims Insulin resistance (IR) is a major risk factor for cardiovascular disease and atherosclerosis. Life-threatening acute events are mainly due to rupture of unstable plaques, and the role of vascular smooth muscle cells (VSMCs) in this process in IR, Type 2 diabetes mellitus, and metabolic syndrome (T2DM/MetS) has not been fully addressed. Therefore, the role of VSMC survival in the generation of unstable plaques in T2DM/MetS and the involvement of inflammatory mediators was investigated. Methods and results Defective insulin receptor substrate 2 (IRS2)-mediated signalling produced insulin-resistant VSMCs with reduced survival, migration, and higher apoptosis than control cells. Silencing…

medicine.medical_specialtyVascular smooth musclePhysiologyCell Survivalmedicine.medical_treatmentMyocytes Smooth MuscleCX3C Chemokine Receptor 1InflammationMice TransgenicBiologyMuscle Smooth VascularInsulin resistanceApolipoproteins EPhysiology (medical)Internal medicinemedicineAnimalsHumansProtein kinase BPI3K/AKT/mTOR pathwayCells CulturedMice KnockoutChemokine CX3CL1Insulinmedicine.diseaseAtherosclerosisIRS2Mice Inbred C57BLAtheromaEndocrinologyDiabetes Mellitus Type 2cardiovascular systemReceptors Chemokinemedicine.symptomInsulin ResistanceCardiology and Cardiovascular MedicineSignal TransductionCardiovascular research
researchProduct

Investigational agents for Crohn's disease.

2010

IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful en…

medicine.medical_specialtybiological therapy. Crohn' s disease. Integrins.Probiotics.Small molecules.DiseaseAdaptive ImmunityReceptors Tumor Necrosis FactorCrohn DiseaseGastrointestinal AgentsmedicineHumansImmunologic FactorsPharmacology (medical)Clinical efficacyIntensive care medicineRandomized Controlled Trials as TopicPharmacologyMitogen-Activated Protein Kinase KinasesBiological therapiesCrohn's diseaseEverolimusEnd pointINVESTIGATIONAL AGENTSbusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineDrugs Investigationalmedicine.diseaseImmunity InnateImmunologyCytokinesRemission rateImmunotherapybusinessCell Adhesion Moleculesmedicine.drugExpert opinion on investigational drugs
researchProduct

Vascular Dysfunction in Nitroglycerininduced Nitrate Tolerance is Improved by Telmisartan Therapy — Suppression of the RAAS and PKC Pathway

2010

medicine.medical_specialtybusiness.industryPharmacologyBiochemistrychemistry.chemical_compoundEndocrinologyNitratechemistryPhysiology (medical)Internal medicinemedicineTelmisartanbusinessProtein kinase Cmedicine.drugFree Radical Biology and Medicine
researchProduct

Regulated Proteolysis of RAGE and AβPP as Possible Link Between Type 2 Diabetes Mellitus and Alzheimer's Disease

2009

Epidemiological studies have linked type 2 diabetes mellitus (T2DM) with an increased risk of developing Alzheimer's disease (AD). In T2DM, the elevated blood glucose level promotes formation of advanced glycation end products (AGEs). The receptor for AGEs (RAGE) is a type I membrane-protein and is also able to import amyloid-beta (Abeta) from the blood across the blood-brain-barrier into the brain. Oligomeric Abeta peptides disturb synaptic function in the brain and are believed to contribute to the development of AD. Abeta peptides are released from the amyloid-beta protein precursor (AbetaPP) after sequential proteolysis by beta- and gamma-secretases but alpha-secretase-mediated cleavage…

medicine.medical_specialtyendocrine system diseasesProteolysisReceptor for Advanced Glycation End ProductsAmyloid beta-Protein PrecursorAlzheimer DiseaseGlycationInternal medicinemental disordersmedicineAnimalsHumansReceptors ImmunologicProtein precursorProtein kinase AReceptorAmyloid beta-Peptidesmedicine.diagnostic_testChemistryGeneral Neurosciencenutritional and metabolic diseasesGeneral MedicinePsychiatry and Mental healthClinical PsychologyCholesterolEndocrinologyDiabetes Mellitus Type 2EctodomainPeptide transportAmyloid Precursor Protein SecretasesGeriatrics and GerontologySignal transductionJournal of Alzheimer's Disease
researchProduct

Increased Connexin 43 Expression as a Potential Mediator of the Neuroprotective Activity of the Corticotropin-Releasing Hormone

2009

CRH is a major central stress mediator, but also a potent neuroprotective effector. The mechanisms by which CRH mediates its neuroprotective actions are largely unknown. Here, we describe that the gap junction molecule connexin43 (Cx43) mediates neuroprotective effects of CRH toward experimentally induced oxidative stress. An enhanced gap junction communication has been reported to contribute to neuroprotection after neurotoxic insults. We show that CRH treatment up-regulates Cx43 expression and gap junctional communication in a CRH receptor-dependent manner in IMR32 neuroblastoma cells, primary astrocytes, and organotypic hippocampal slice cultures. MAPKs and protein kinase A-cAMP response…

medicine.medical_specialtyendocrine systemCorticotropin-Releasing HormoneMAP Kinase Signaling SystemCarbenoxoloneConnexinBiologyNeuroprotectionModels BiologicalArticleRats Sprague-DawleyCorticotropin-releasing hormoneMiceEndocrinologyMediatorInternal medicineCell Line Tumormedicinepolycyclic compoundsAnimalsHumansProtein kinase AMolecular BiologyGap junctionBrainGap JunctionsGeneral MedicineCell biologyRatsEndocrinologyNeuroprotective Agentsnervous systemGene Expression RegulationConnexin 43cardiovascular systemSignal transductionhormones hormone substitutes and hormone antagonistsmedicine.drugSignal Transduction
researchProduct

Bafetinib inhibits functional responses of human eosinophils in vitro

2012

Eosinophils play a prominent role in the process of allergic inflammation. Non-receptor associated Lyn tyrosine kinases generate key initial signals in eosinophils. Bafetinib, a specific Abl/Lyn tyrosine kinase inhibitor has shown a potent antiproliferative activity in leukemic cells, but its effects on eosinophils have not been reported. Therefore, we studied the effects of bafetinib on functional and mechanistic responses of isolated human eosinophils. Bafetinib was more potent than non-specific tyrosin kinase comparators genistein and tyrphostin inhibiting superoxide anion triggered by N-formyl-Met-Leu-Phe (fMLF; 100 nM) (−log IC50=7.25±0.04 M; 6.1±0.04 M; and 6.55±0.03 M, respectively).…

medicine.medical_specialtymedicine.drug_classFarmacologíaGenisteinApoptosisPharmacologyBiologyTyrosine-kinase inhibitorAllergic inflammationchemistry.chemical_compoundCell MovementSuperoxidesLYNInternal medicinemedicineHumansProtein Kinase InhibitorsPeroxidasePharmacologyKinaseEosinophil Cationic ProteinGranulocyte-Macrophage Colony-Stimulating FactorEosinophilLeukotriene C4Respiratory burstEosinophilsN-Formylmethionine Leucyl-PhenylalaninePyrimidinesmedicine.anatomical_structureEndocrinologychemistryCalciumInterleukin-5Tyrosine kinaseEuropean Journal of Pharmacology
researchProduct

Protein kinase C-inhibiting properties of the losartan metabolite EXP3179 make the difference.

2009

The inhibition of the renin-angiotensin axis with the angiotensin II (ATII) receptor blockers, such as losartan, candesartan, and valsartan, has been demonstrated, similar to angiotensin-converting enzyme inhibitors, to reduce mortality in patients with arterial hypertension, chronic congestive heart failure, and acute myocardial infarction.1 Initially, the ATII receptor antagonist losartan helped to demonstrate new classes of ATII receptors and substantially expanded our knowledge about the cardiovascular effects of the renin-angiotensin-aldosterone system and its effector peptide ATII. Researchers dealing with this compound soon revealed that, beyond its antihypertensive effects attribute…

medicine.medical_specialtymedicine.drug_classMetabolitePharmacologyLosartanchemistry.chemical_compoundInternal medicineInternal MedicinemedicineHumansReceptorProtein Kinase CPhagocytesNADPH oxidasebiologyNADPH OxidasesReceptor antagonistAngiotensin IICandesartanEndocrinologyLosartanchemistryValsartanMatrix Metalloproteinase 9Hypertensionbiology.proteinAngiotensin II Type 1 Receptor Blockersmedicine.drugHypertension (Dallas, Tex. : 1979)
researchProduct